Mount Sinai Genomics Spinout Sema4 Goes Public Under $500M SPAC Deal

Sema4

Stamford, CT-based Sema4, a genomics company spun out of Mount Sinai Health System, completed its merger with special purpose acquisition company CM Life Sciences today.

Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, will begin trading on the Nasdaq under SMFR tomorrow.

The transaction values Sema4 at an enterprise value of approximately $2 billion.

Announced in February, the deal is expected to provide aproximately $500 million in cash proceeds to shareholders and Sema4. Read more.

Total
0
Shares
Related Posts